Somapacitan (NNC0195-0092)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Somapacitan (NNC0195-0092), covering 2020-10-06 to 2020-10-06. Get the full timeline:
Most recent: Clinical Trial Update: A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency [Phase 3]